Atopic Dermatitis – M16-047 (extension to M18-891)

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis

For more information, please click here.

Register Today!

Trial Information

Start DateMarch 2024
End Date~2030
Number of Visits12 visits, 11 Phone calls every 24 weeks
StatusIn Follow-up

For additional information
on this trial contact: